Fierce 15 highlights pre-commercial biotech companies driving the next generation of therapies for patients worldwide
Cambridge, UK, 22 September 2025: TRIMTECH Therapeutics, a biotech company creating novel, small molecule therapeutics that selectively degrade protein aggregates to combat neurodegenerative diseases, today announced that it has been named as one of Fierce Biotech’s 2025’s ‘Fierce 15’ for 2025. The selection recognises the Company as one of the most innovative and promising private biotechnology companies in the industry.
TRIMTECH is addressing the urgent need for cost-effective disease-modifying treatments for neurodegenerative disorders, such as Alzheimer’s, that can reach broad patient populations. The Company is creating novel, highly selective, small molecule targeted protein degraders designed to clear the toxic protein assemblies that drive neurodegenerative and inflammatory diseases. Built on decades of pioneering research into the protein TRIM21, a novel E3-ligase, TRIMTECH’s degraders can potently and selectively degrade protein aggregates and oligomeric complexes, while preserving normal monomeric proteins – and therefore healthy cellular function.
Earlier this year the Company announced the closing of an oversubscribed $31 million (£25 million) seed funding round, led by Cambridge Innovation Capital (CIC) and SV Health Investors’ Dementia Discovery Fund (DDF), with participation from Pfizer Ventures, M-Ventures, Eli Lilly, and MPH. The team was later delighted when co-founder Dr Leo James was elected as a Fellow of the Royal Society (FRS), one of the highest honours for a UK scientist. In September the Company announced the first two members of its Scientific Advisory Board, prominent targeted protein degradation experts Prof. Alessio Ciulli FRS (as Chair) and Dr Adam Gilbert.
We are honoured to have been selected by Fierce Biotech as one of their ‘Fierce 15’. This really is testament to the potential of our approach, and recognition of the milestones we have already achieved. Neurodegenerative and inflammatory disorders such as Alzheimer’s remain areas of profound unmet need – patients cannot wait for solutions that only reach a few. Our approach is designed to pair cutting-edge selectivity with small-molecule practicality, opening new targets. With strong momentum behind us, an impressive investor syndicate and an incredible team of experts on board, we’re focused on continuing to build the foundations for clinical translation, to deliver accessible medicines that change the trajectory of common, aggregation-driven diseases.
Over the past 23 years, our Fierce 15 special report has spotlighted the private biotechs pushing science into uncharted territory, whose approaches and discoveries represent genuine leaps forward. This year we’ve selected 15 pre-commercial biotechs that are advancing transformative science in an unrelenting industry landscape. These companies exemplify the innovation and determination driving the next generation of therapies that will hopefully benefit patients worldwide.
An internationally recognized daily report reaching a network of over 300,000 biotech and pharma industry professionals, Fierce Biotech provides subscribers with an authoritative analysis of the day’s top stories. Every year Fierce Biotech evaluates hundreds of early-stage companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.
Contact:
Zyme Communications
Katie Odgaard
Katie.odgaard@zymecommunications.com
About TRIMTECH Therapeutics Ltd.
TRIMTECH Therapeutics is creating novel, highly selective, small molecule targeted protein degraders, to combat neurodegenerative and inflammatory diseases. Founded on decades of pioneering academic research into the protein TRIM21, a novel E3-ligase, the Company has demonstrated its ‘TRIMTAC’ degraders can recapitulate degradation seen with other modalities (vectors and antibodies) whilst leaving the functional monomeric form of the target protein intact and able to support healthy cellular function. TRIMTECH’s approach opens up much needed small molecule approaches for indications that affect very large populations, such as Alzheimer’s disease.
TRIMTECH was founded in 2023 by its academic co-founders Leo James, PhD FRS (MRC Laboratory of Molecular Biology) and Will McEwan, PhD (UK Dementia Research Institute, University of Cambridge), with Cambridge Innovation Capital (CIC) and SV Health Investors’ Dementia Discovery Fund (DDF) in conjunction with their joint entrepreneur-in-residence, Dr Damian Crowther.
TRIMTECH is led by a highly experienced team with vast expertise in targeted protein degradation (TPD). In March 2025 the Company announced $31 million (£25 million) seed funding round, led by CIC and DDF, with M Ventures and Pfizer Ventures joining. Additional investors also include Eli Lilly and Company, MP Healthcare Venture Management (MPH), Cambridge Enterprise Ventures, and Start Codon.
